TRUST-II: A global phase II study for taletrectinib in ROS1 fusion-positive lung cancer and other solid tumors.-MedSci.cn - 梅斯（MedSci）

TRUST-II: A global phase II study for taletrectinib in ROS1 fusion-positive lung cancer and other solid tumors.

Nagasaka, M; Sugawara, S; Choi, CM; Okamoto, T; Yanagitani, N; Nosaki, K; Takahashi, T; Fujiwara, Y; Hayashi, H; Khoury, J; Nieva, JJ; Gabayan, AE; Raez, LE; Chen, HB; Dimou, A; Pennell, NA; Liu, G; Ou, SHI; Seto, T; Ohe, Y

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务